Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E53.91 EPS (ttm)6.30 Insider Own1.00% Shs Outstand108.73M Perf Week-4.16%
Market Cap36.91B Forward P/E21.89 EPS next Y15.51 Insider Trans-1.39% Shs Float77.33M Perf Month-13.94%
Income725.80M PEG2.85 EPS next Q2.62 Inst Own71.10% Short Float4.88% Perf Quarter-6.70%
Sales4.44B P/S8.32 EPS this Y85.10% Inst Trans-0.72% Short Ratio4.01 Perf Half Y-36.65%
Book/sh36.10 P/B9.40 EPS next Y43.12% ROA13.70% Target Price473.48 Perf Year-34.62%
Cash/sh7.81 P/C43.47 EPS next 5Y18.89% ROE20.70% 52W Range341.00 - 605.93 Perf YTD-37.47%
Dividend- P/FCF46.49 EPS past 5Y44.90% ROI16.00% 52W High-43.97% Beta1.07
Dividend %- Quick Ratio3.10 Sales past 5Y55.00% Gross Margin90.50% 52W Low-0.45% ATR11.24
Employees4300 Current Ratio3.40 Sales Q/Q38.10% Oper. Margin28.90% RSI (14)30.87 Volatility3.55% 2.81%
OptionableYes Debt/Eq0.10 EPS Q/Q118.60% Profit Margin16.40% Rel Volume1.37 Prev Close357.14
ShortableYes LT Debt/Eq0.10 EarningsMay 05 BMO Payout0.00% Avg Volume941.16K Price339.48
Recom2.30 SMA20-10.32% SMA50-11.87% SMA200-25.42% Volume1,287,308 Change-4.94%
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Sep-01-15Initiated Raymond James Outperform $615
Aug-31-15Downgrade Chardan Capital Markets Buy → Neutral $565
Jun-24-16 08:22PM  [$$] Biotech Labs Birth New Drugsand New Fortunes at The Wall Street Journal
04:34PM  How Does Brexit Affect Biotech Stocks? Wall Street Weighs In
Jun-23-16 10:10AM  Company News for June 23, 2016
Jun-22-16 04:57PM  Medicare 'Death Panel' Is On Ice; Biotechs Rally
04:04PM  Verifone, Biogen Crash Wednesdays 52-Week Low Club at 24/7 Wall St.
03:56PM  Regeneron Tries to Recover From Lows
12:51PM  Stocks Erased Gains; Biotechs, KB Home Jump As Tesla Dives
10:50AM  Biotech: Why Take the Risk? at Barrons.com
Jun-21-16 06:14PM  This Is the Most Important Business Trend in Pharma at Fortune
04:43PM  Why Biotech is Getting Crushed at Barrons.com
Jun-20-16 05:07PM  5 Of The Hottest Stocks To Own During The Summer
Jun-17-16 04:10PM  Cisco, Regeneron, Skyworks, Skechers Lead Insider Trades
10:14AM  More Fovista Risk For Regeneron Than Investors Realize: Canaccord at Barrons.com
Jun-15-16 06:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-14-16 04:44PM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
04:20PM  3 Biotech Stocks to Buy If the Market Crashes at Motley Fool
11:01AM  Regeneron: Nine Reasons Praluent Could Be Forced From the US Market at Barrons.com
Jun-13-16 12:05PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : June 13, 2016
09:00AM  5 Top Stocks to Buy in June at Motley Fool
Jun-10-16 09:00PM  Should You Listen to the Rich?: Jim Cramer's Best Blogs
01:15PM  4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
07:00AM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
Jun-09-16 08:17PM  UPDATE: Biotech Stocks: Much Ado About Nothing at ASCO? at Barrons.com
04:40PM  Why Ophthotech Corp. Shares Soared 14.9% in May at Motley Fool
05:01AM  The X-Men Approach to Medicine at Bloomberg
Jun-08-16 02:21PM  What Helped Incyte Report Growth in 1Q16?
11:33AM  Biotech Stocks: Wait Until Next Year at Barrons.com
Jun-06-16 09:52AM  Regeneron, Sanofi Report Positive Dupilumab Phase III Data
01:27AM  Sanofi and Regeneron report positive skin disease trial Reuters
01:00AM  Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients PR Newswire
Jun-03-16 02:18PM  Biotech: What's the Trade? at Barrons.com
Jun-02-16 10:23AM  Biotech Stocks: Don't Expect a 'Miraculous Recovery' at Barrons.com
Jun-01-16 01:40PM  Regeneron: Coming Into Its Own at Barrons.com
10:00AM  Regeneron Reports Interim Data on Cholesterol Lowering Drug
May-31-16 07:00PM  Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age
06:46PM  How to Discover the Best Biotechs in the World
12:01PM  Regeneron Presents Favorable Interim Data From Stage 2 Proof-Of-Concept Trial Of Evinacumab
09:00AM  Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia PR Newswire
12:07AM  New Eczema Treatments Could Be Available Soon at The Wall Street Journal
May-27-16 03:00PM  The 'Nobel Prize of high school competitions' just got the most money it's received in a century from a biotech giant
08:22AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche at Motley Fool
May-26-16 08:30AM  Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search PR Newswire
12:12AM  [$$] Regeneron Named as Science Talent Search Sponsor at The Wall Street Journal
12:01AM  [$$] Regeneron Named as Science Talent Search Sponsor at The Wall Street Journal
12:00AM  Biotech Regeneron replaces Intel as sponsor of Science Talent Search
May-25-16 09:16PM  [$$] Biotech Named as Sponsor at The Wall Street Journal
May-24-16 06:04PM  Lilly says new type of pain drug could lessen need for opioids Reuters
12:24PM  Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why at Motley Fool
09:03AM  How I Made a Huge Profit on Regeneron -- And It was One of My Biggest Mistakes Ever
May-23-16 07:44PM  Sanofi Is Shuffling Its Exec Roster Amid Continued Struggles at Fortune
May-19-16 02:40PM  Why Albany added 1,400 private sector jobs instead of losing 800 at bizjournals.com
May-18-16 01:30PM  History Says Now Is The Time To Buy This Biotech Firm
12:02PM  Regeneron Pharmaceuticals (REGN) Stock is the 'Chart of the Day' at TheStreet
May-17-16 05:54PM  After-hours buzz: Alphabet, LendingClub, Target & more at CNBC
05:54PM  After-hours buzz: Alphabet, LendingClub, Target & more at CNBC
05:43PM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Ophthotech at Motley Fool
11:57AM  IBBs Large Caps: Regeneron Pharmaceuticals Rose 6%
08:05AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : May 17, 2016
07:06AM  Regenerons Target Price Downgraded by Wall Street Analysts
04:38AM  Pfizer's Anacor deal showcases new wave of eczema therapies
May-16-16 06:07PM  Regeneron Pharmaceuticals Collaboration Revenue in 1Q16 +6.09%
05:33PM  Pfizer Acquiring Anacor For Potential Blockbuster Eczema Drug
05:33PM  Pfizer Acquiring Anacor For Potential Blockbuster Eczema Drug at Investor's Business Daily
04:30PM  Regeneron's Spike Not Tied to Pfizer-Anacor Deal, But It Doesn't Hurt at TheStreet
03:26PM  3 Stocks You Can Buy and Hold Forever at Motley Fool
03:04PM  Drug developer negotiating deal to buy Pitney Bowes building at American City Business Journals
01:10PM  Big Biotech: What's the Worst Case Scenario? at Barrons.com
12:45PM  4 Stocks, 4 trades: BAC, REGN & more CNBC
May-14-16 06:24PM  Barron's Picks And Pans: Regeneron, Axalta, Alleghany And More Benzinga
06:40AM  5 Growth Stocks to Buy in May at Motley Fool
12:01AM  This Weekend's Barron's: Regeneron: Best Bet in Biotech ~ Alleghany Has Big Potential ~ Axalta Could Rally in the Next Year ~ Ryanair Is Set to Soar ~ Playing China's Latest Boom at Barrons.com
12:01AM  [$$] Regeneron: The Best Bet in Biotech Stocks at Barrons.com
May-13-16 06:06PM  How Can Regeneron Pharmaceuticals Boost Revenue from Praluent? Market Realist
May-12-16 03:14PM  Regeneron CEO says drug price critique by independent group unscientific Reuters
03:07PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : May 12, 2016 at Capital Cube
11:07AM  How Did Regenerons Key Drug Eylea Perform in 1Q16? Market Realist
May-11-16 04:18PM  Another Major Insurer Is Tying Drug Prices to Health Outcomes at Fortune
01:04PM  REGENERON PHARMACEUTICALS INC Financials EDGAR Online Financials
10:03AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
09:14AM  XLV Gains May 10, Trades above Its 20-Day Moving Average Market Realist
May-10-16 10:39AM  Did Regeneron Pharmaceuticals Beat Earnings Expectations in 1Q16? Market Realist
May-09-16 10:16AM  Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss Zacks
May-08-16 06:05AM  How Did Regeneron Land Such a Premium Valuation? Market Realist
May-07-16 12:02PM  Eylea's Growth Propels Regeneron Pharmaceuticals Inc Shares Higher at Motley Fool
May-06-16 12:01PM  Roadblocks to Regeneron's Blockbusters at Bloomberg
11:30AM  Gene editing firm Intellia raises $163M in largest biotech IPO of 2016 at American City Business Journals
May-05-16 04:20PM  9 Figures That Sum Up Regeneron Pharmaceuticals' First Quarter at Motley Fool
03:48PM  Regeneron secures more coverage for cholesterol drug Praluent Reuters
02:08PM  Edited Transcript of REGN earnings conference call or presentation 5-May-16 12:30pm GMT Thomson Reuters StreetEvents
01:22PM  [$$] Regeneron Raises Sales Expectations for Eylea at The Wall Street Journal
12:41PM  Regeneron Up As Eylea Beats Views; Merck Down As Lead Drugs Slip at Investor's Business Daily
12:17PM  Can XLV Maintain Stability in May? Market Realist
10:42AM  Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View Zacks
10:09AM  Regeneron Pharmaceuticals: The Eyleas Have It at Barrons.com
08:45AM  Regeneron (REGN) Beats on Q1 Earnings and Revenues Zacks
08:32AM  Morning Movers: Regeneron Gains on Earnings; Chesapeake Energy Flies at Barrons.com
08:17AM  Regeneron (REGN) Misses on Q1 Earnings, Beats on Revenues Zacks
07:16AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
07:07AM  Q1 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:42AM  Regeneron beats 1Q profit forecasts AP
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 02Sale549.0343,34823,799,539500,000Dec 04 04:13 PM
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM
BROWN MICHAEL SDirectorSep 21Option Exercise57.113,000171,3303,000Sep 22 02:39 PM
BROWN MICHAEL SDirectorSep 21Sale551.553,0001,654,6500Sep 22 02:39 PM
BAKER CHARLES ADirectorSep 17Option Exercise18.615,00093,05014,000Sep 18 04:06 PM
BAKER CHARLES ADirectorSep 17Sale550.005,0002,750,0009,000Sep 18 04:06 PM
SCHLEIFER LEONARD SPresident & CEOSep 02Option Exercise402.697,2262,909,83849,313Sep 03 04:59 PM
LAROSA JOSEPH JSVP General Counsel and SecretSep 01Option Exercise59.201,68999,98916,756Sep 02 04:04 PM
Powchik PeterSVP Clinical Development & RegAug 14Sale573.3823,48513,465,86615,821Aug 17 04:01 PM
Powchik PeterSVP Clinical Development & RegAug 13Option Exercise117.3360,3617,082,07046,299Aug 17 04:01 PM
POON CHRISTINE ADirectorAug 12Sale564.1611263,186790Aug 12 04:45 PM
POON CHRISTINE ADirectorAug 11Option Exercise273.67470128,6251,125Aug 12 04:45 PM
GILMAN ALFRED GDirectorAug 06Option Exercise57.115,000285,55013,912Aug 07 06:15 PM
GILMAN ALFRED GDirectorAug 06Sale587.125,0002,935,6018,912Aug 07 06:15 PM
Terifay Robert JSVP CommercialAug 06Sale588.9713,4237,905,78123,293Aug 07 06:14 PM
Terifay Robert JSVP CommercialAug 05Option Exercise30.6332,500995,47552,529Aug 07 06:14 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Option Exercise270.435,0001,352,1509,745Aug 05 08:58 PM
Landry Robert ESVP Finance & CFOAug 05Option Exercise272.704,0001,090,80011,099Aug 06 09:00 PM
Tessier-Lavigne MarcDirectorAug 05Option Exercise57.115,000285,5506,187Aug 05 08:55 PM
Landry Robert ESVP Finance & CFOAug 05Sale592.844,0002,371,3507,099Aug 06 09:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Sale585.535,0002,927,6484,945Aug 05 08:58 PM
Tessier-Lavigne MarcDirectorAug 05Sale590.265,0002,951,2751,187Aug 05 08:55 PM
GOLDSTEIN JOSEPH LDirectorAug 04Sale586.002,0001,172,00014,000Aug 05 10:03 AM
GOLDSTEIN JOSEPH LDirectorJul 15Sale550.002,0001,100,00016,000Jul 15 04:09 PM